glp-1 like supplements Support Probiotic + Protein Stack GLP-1 Companion Health Pack Daily

For laboratory and research use only.

There have been and continue to be advances in the GLP-1 pipeline.

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

Conclusion Significant weight regain occurred 8 weeks after discontinuation of AOMs and was sustained through 20 weeks

CU Cancer Center member Bryan Haugen, MD, breaks down the science behind the FDA warning on the GLP-1 weight-loss medications.

Big news